CIN1 Clinical Trial
Official title:
Efficacy of Topical 95% Trichloroaceteic Acid in the Treatment of CIN 1 or Less After Low-grade Abnormality of Screening Test: A Randomized Controlled Trial
Verified date | August 2023 |
Source | Rajavithi Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the efficacy of topical 95% TCA in the treatment of CIN 1 or less after low grade abnormality of screening test
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 1, 2023 |
Est. primary completion date | December 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Women who have low-grade abnormality result such as ASC-US, LSIL, HPV 16/18 positive, persistent HPV infection after cervical cancer screening test - No history of endometrial or cervical cancer - Pregnancy test negative - Good communication in Thai language - Vouluntarily participate to the study Exclusion Criteria: - Pregnancy test positive after participate in the study - Pathologic result from colposcopic biopsy (before intervention) is high-grade abnormality such as HSIL, CIN2-3 or AIS |
Country | Name | City | State |
---|---|---|---|
Thailand | Rajavithi hospital | Phaya Thai | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Rajavithi Hospital |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with cytologic examination, HPV testing and colposcopic examination with biopsy ( Efficacy of 95%Trichloroacetic acid in the treatment of CIN1 or less) | using cytologic examination, HPV testing and colposcopic examination with biopsy (if having lesion) compare to previous results
If all of the test's results are normal, we consider it as remission of CIN1 or less *normal means: Cytologic examination = Negative for intraepithelial lesion or malignancy HPV testing = no HPV detected Colposcopic examination not seen any lesion = normal (not perform biopsy) Colposcopic examination with biopsy = normal pathlogic result |
6 months after intervention | |
Secondary | Pain after treatment which evaluated by using visual analogue scale | Sides effect of 95%Trichloroacetic acid | immediately after intervention, up to 2 weeks after intervention | |
Secondary | Having leukorrhea or not? which is recorded by questionnaire | Sides effect of 95%Trichloroacetic acid | immediately after intervention, up to 2 weeks after intervention | |
Secondary | Having abnormal vaginal bleeding or not? which is recorded by questionnaire | Sides effect of 95%Trichloroacetic acid | immediately after intervention, up to 2 weeks after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05372016 -
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Recruiting |
NCT05027776 -
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
|
Phase 3 | |
Completed |
NCT03676101 -
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 1 | |
Recruiting |
NCT04895020 -
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
|
Phase 3 | |
Completed |
NCT04425291 -
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Recruiting |
NCT05371353 -
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
|
||
Completed |
NCT04607850 -
Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions
|
Phase 1/Phase 2 | |
Recruiting |
NCT05916911 -
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
|
Phase 4 | |
Terminated |
NCT05584332 -
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Recruiting |
NCT04422366 -
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Completed |
NCT02405533 -
Phase II Evaluation of AHCC for the Eradication of HPV Infections
|
N/A |